C3 partners with 16 LGMD organizations in letter to FDA
Coalition to Cure Calpain 3 is proud to be one of 17 organizations dedicated to LGMD to have collaborated on a statement submitted to the Food and Drug Administration in conjunction with the recent Patient-Focused Drug Development Meeting Patient Perspectives on Gene Therapy Products.
Advancing Excellence in LGMD Diagnosis, Care, and Emerging Therapies (CME Accreditation) 📅 13-14 November 2026 | 📍 Atlanta, Georgia As new therapies move closer to clinical practice, the need for accurate diagnosis, specialist knowledge, and coordinated multidisciplinary care has never been greater. Developed for healthcare professionals involved in the diagnosis and management of limb-girdle muscular... Read More
A new paper, “CaMKIIβ Signaling drives expression of metabolic and stress response genes in skeletal muscle, and its loss contributes to the LGMDR1 phenotype,” was recently published in the journal Human Molecular Genetics. It was authored by a multi-institutional group led by Dr. Melissa Spencer, C3 Scientific Advisory Board Chair and Professor of Neurology and... Read More